Balanced news tone
News Sentiment
CRMD sentiment intelligence
CorMedix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
59
Balanced news tone
56 relevant articles
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-0.8% over one week, +8.6% over four weeks, trend inactive, and near fair-value range.
Why (CRMD) Price Action Is Critical for Tactical Trading
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Earnings
75/100 classification
One-week reaction
-0.8%
Price digesting
Trend fit
Trend inactive
8.6% over four weeks
Fair value
14.6%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
24
Neutral
24
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Dialysis drug DefenCath drives $97.5M in Q1 sales as CorMedix lifts 2026 targets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
How The CorMedix (CRMD) Story Is Shifting As Analysts Split On US$13–US$15 Targets
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 May 2026 07:00
- Source
- Market source
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets
- Tone
- Negative 34/100
- Event
- Guidance
- Published
- 08 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Market source
Market source
Direct company coverage
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 24 Mar 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 19 Mar 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 Mar 2026 08:00
- Source
- Market source
Market source
Direct company coverage
Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 01 Mar 2026 08:00
- Source
- Market source
simplywall.st
Direct company coverage
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 28 Feb 2026 08:00
- Source
- simplywall.st
Market source
Direct company coverage
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 17 Feb 2026 08:00
- Source
- Market source
Market source
Direct company coverage
CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 11 Feb 2026 08:00
- Source
- Market source
simplywall.st
Direct company coverage
CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- simplywall.st
Market source
Direct company coverage
Is CorMedix (CRMD) Offering An Opportunity After Its Recent 43% Share Price Slide
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Jan 2026 08:00
- Source
- Market source
Stocktwits
Direct company coverage
CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jan 2026 08:00
- Source
- Stocktwits
Market source
Direct company coverage
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 26 Dec 2025 08:00
- Source
- Market source
Stocktwits
Direct company coverage
Why Is CorMedix Stock Rising Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Dec 2025 08:00
- Source
- Stocktwits
simplywall.st
Industry context
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 Dec 2025 08:00
- Source
- simplywall.st
TradingView
Direct company coverage
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 14 Oct 2025 07:00
- Source
- TradingView
simplywall.st
Direct company coverage
Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts
- Tone
- Positive 82/100
- Event
- Analyst action
- Published
- 27 Jun 2025 07:00
- Source
- simplywall.st
INDmoney
Direct company coverage
CorMedix Inc. (CRMD) Live Share Price, Invest From India
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Apr 2025 10:44
- Source
- INDmoney